Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China flag China · Delayed Price · Currency is CNY
3.260
+0.040 (1.24%)
Sep 7, 2026, 3:04 PM CST

SHE:002589 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
5,7473,7454,9845,0615,3404,579
Trading Asset Securities
5-----
Cash & Short-Term Investments
5,7523,7454,9845,0615,3404,579
Cash Growth
-3.80%-24.87%-1.52%-5.23%16.63%-20.97%
Accounts Receivable
3,8434,1764,3754,2224,60311,276
Other Receivables
674.32717.08893.29990.011,6701,897
Receivables
4,5184,8935,2695,2126,27413,172
Inventory
631.43715.3734.741,119954.512,068
Prepaid Expenses
0.17--0.11-7.27
Other Current Assets
121.16100.4296.79147.07250.97845.88
Total Current Assets
11,0239,45311,08411,53912,82020,672
Property, Plant & Equipment
1,9972,0182,2392,2772,2972,527
Long-Term Investments
921.33821.33746.72852.03594.07805.82
Goodwill
146.67146.67146.67146.67146.69620.27
Other Intangible Assets
488.25506.7440.89552.39624.21478.35
Long-Term Accounts Receivable
-----0.07
Long-Term Deferred Tax Assets
312.03321.59286.15284.44106.68122.86
Long-Term Deferred Charges
44.9949.6961.2660.8789.93134.58
Other Long-Term Assets
1,0161,0531,033996.391,6541,035
Total Assets
15,94914,37016,03816,70918,33226,397

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
4,8503,7603,3833,7237,7159,791
Accrued Expenses
27.4838.9543.0366.9857.68227.5
Short-Term Debt
4,7894,2016,0976,5563,9264,440
Current Portion of Long-Term Debt
172.35167.83155.385.66.516.3
Current Portion of Leases
-0.860.760.521.8210.09
Current Income Taxes Payable
0.831.523.641.68591.82
Current Unearned Revenue
23.169.4425.1329.1232.43174.72
Other Current Liabilities
371.4482.59237.28378.53724.461,766
Total Current Liabilities
10,2348,6629,94510,76112,46816,508
Long-Term Debt
215.28234.71327.08261.2767.248.5
Long-Term Leases
1.470.934.120.842.7339.19
Long-Term Unearned Revenue
4.394.574.741.621.9317.5
Long-Term Deferred Tax Liabilities
42.7644.9648.547.4840.5883.56
Other Long-Term Liabilities
-----7.28
Total Liabilities
10,4988,94710,32911,07212,58116,704

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,5051,5051,5051,5051,5051,505
Additional Paid-In Capital
3,4773,4773,6343,7203,7014,015
Retained Earnings
428.56419.59409.44453.83432.662,278
Treasury Stock
-101.48-101.48--230.65-230.65-230.65
Total Common Equity
5,3095,3005,5485,4485,4077,567
Minority Interest
142.25123.11160.2189.183442,126
Shareholders' Equity
5,4515,4235,7095,6375,7519,693
Total Liabilities & Equity
15,94914,37016,03816,70918,33226,397

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
5,1784,6056,5846,8244,0044,544
Net Cash (Debt)
573.9-860.3-1,600-1,7641,33634.82
Net Cash Growth
----3737.34%-
Net Cash Per Share
0.36-0.54-1.30-1.170.900.02
Filing Date Shares Outstanding
1,4701,4701,5051,4961,4961,496
Total Common Shares Outstanding
1,4701,4701,5051,4961,4961,496
Working Capital
788.12791.181,140777.98351.124,164
Book Value Per Share
3.613.613.693.643.615.06
Tangible Book Value
4,6744,6464,9614,7494,6366,468
Tangible Book Value Per Share
3.183.163.303.173.104.32
Buildings
2,1061,8211,9741,8191,8651,468
Machinery
624.81602.5687.24695.38778.651,436
Construction In Progress
18.82306.18307.34429.34315.37549.58